RecruitingPhase 2NCT07021989

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Sponsor

Michael Spinner, MD

Enrollment

38 participants

Start Date

Aug 18, 2026

Study Type

INTERVENTIONAL

Conditions

Refractory Hodgkin Lymphoma Classic Hodgkin Lymphoma Hodgkin Lymphoma, Adult

Summary

This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investigate using circulating tumor DNA (ctDNA) at pre-determined time points using Foresight CLARITY LDT, an ultra-sensitive liquid biopsy platform that detects Minimal residual disease (MRD) in patients with B-cell lymphomas using the phased variant enrichment and sequencing technology (PhasEDq) to determine response to study interventions.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT), a medical device called Foresight CLARITY™ LDT, and others for people with classic hodgkin lymphoma, hodgkin lymphoma, adult, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPembrolizumab

Given intravenously

RADIATIONNon-investigational, involved site radiotherapy (ISRT)

Undergo possible, standard of care, non-investigational radiation therapy

DRUGGemcitabine

Given IV

DRUGVinorelbine

Given IV

DRUGLiposomal Doxorubicin

Given IV

DEVICEForesight CLARITY™ LDT

Foresight CLARITY LDT, a laboratory-developed test (LDT),by Foresight Diagnostics, is an ultra-sensitive liquid biopsy and tissue platform that detects MRD in patients with B-cell lymphomas

DRUGPegfilgrastim

Given IV for supportive care

PROCEDUREFluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)

Undergo imaging